Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater

Journal of Clinical Pathology

Volumn 65, Issue 2, 2012, Pages 140-145

  Piscuoglio, Salvatore ^a   Lehmann, Frank S ^b   Zlobec, Inti ^a   Tornillo, Luigi ^a   Dietmaier, Wolfgang ^c   Hartmann, Arndt ^d   Wünsch, Peter H ^e   Sessa, Fausto ^f   Rümmele, Petra ^c   Baumhoer, Daniel ^a   Terracciano, Luigi M ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e Municipal Hospital Nürnberg   (Germany)

^f UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CD133 ANTIGEN; CD44V ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE;

ADENOMA; ADULT; ARTICLE; CANCER STEM CELL; CANCER TISSUE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SURVIVAL; TISSUE MICROARRAY; TUMOR CELL; VATER PAPILLA;

ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPULLA OF VATER; ANTIGENS, CD; ANTIGENS, CD44; ANTIGENS, NEOPLASM; CARCINOMA; CELL ADHESION MOLECULES; CELL ADHESION MOLECULES, NEURONAL; COMMON BILE DUCT NEOPLASMS; FEMALE; FETAL PROTEINS; GLYCOPROTEINS; HUMANS; INTESTINAL MUCOSA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PEPTIDES; PROGNOSIS; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84856121002     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200043     Document Type: Article

References (54)

1. Allescher HD. Papilla of Vater: structure and function. Endoscopy 1989;21(Suppl 1):324-9.
2. Neoptolemos JP, Talbot IC, Carr-Locke DL, et al. Treatment and outcome in 52 consecutive cases of ampullary carcinoma. Br J Surg 1987;74:957-61.
3. Goodman MT, Yamamoto J. Descriptive study of gallbladder, extrahepatic bile duct, and ampullary cancers in the United States, 1997-2002. Cancer Causes Control 2007;18:415-22.
4. Brennan MF. Surgical management of peripancreatic cancer. In: Bland KL, Karakoukis CP, Copeland EM, eds. Atlas of Surgical Oncology. Philadelphia, PA: WB Saunders Company, 1995:473.
5. Fisher HP, Zhou H. Pathogenesis of carcinoma of the papilla of Vater. J Hepatobiliary Pancreat Surg 2004;11:301-9.
6. Benhamiche AM, Jouve JL, Manfredi S, et al. Cancer of the ampulla of Vater: results of a 20-year population-based study. Eur J Gastroenterol Hepatol 2000;12:75-9.
7. Albores-Saavedra J, Schwartz AM, Batich K, et al. Cancers of the ampulla of Vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol 2009;100:598-605.
8. Wright NH, Howe JR, Rossini FP, et al. Tumours of the small intestine. In: Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System. IARC, 2000:69-92.
9. Di Giorgio A, Alfieri S, Rotondi F, et al. Pancreatoduodenectomy for tumors of Vater's ampulla: report on 94 consecutive patients. World J Surg 2005;29:513-18.
10. Albores-Saavedra J, Henson DE, Klimstra DS. Tumors of the Gallbladder, Extrahepatic Bile Ducts, and Ampulla of Vater. Washington, DC: Armed Forces Institute of Pathology, 2000:259-316.
11. Schirmacher P, Büchler MW. Ampullary adenocarcinomaddifferentiation matters. BMC Cancer. Lyon, 2008;8:251.
12. Talamini MA, Moesinger RC, Pitt HA, et al. Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg 1997;225:590-9.
13. Dorandeu A, Raoul JL, Siriser F, et al. Carcinoma of the ampulla of Vater: prognostic factors after curative surgery: a series of 45 cases. Gut 1997;40:350-5.
14. Westgaard A, Tafjord S, Farstad IN, et al. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer 2008;8:170.
15. Sessa F, Furlan D, Zampatti C, et al. Prognostic factors for ampullary adenocarcinomas: tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability. Virchows Arch 2007;451:649-57.
16. Park S, Kim SW, Kim SH, et al. Lack of microsatellite instability in neoplasms of ampulla of Vater. Pathol Int 2003;53:667-70.
17. Achille A, Biasi MO, Zamboni G, et al. Cancers of the papilla of Vater: mutator phenotype is associated with good prognosis. Clin Cancer Res 1997;3:1841-7.
18. Imai Y, Tsurutani N, Oda H, et al. Genetic instability and mutation of the TGF-beta-receptor- II gene in ampullary carcinomas. Int J Cancer 1998;76:407-11.
19. Suto T, Habano W, Sugai T, et al. Infrequent microsatellite instability in biliary tract cancer. J Surg Oncol 2001;76:121-6.
20. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol 2005;15:494-501.
21. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
22. Alison MR, Islam S. Attributes of adult stem cells. J Pathol 2009;217:144-60.
23. Lugli A, Iezzi G, Hostettler I, et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010;103:382-90.
24. Mulder JW, Kruyt PM, Sewnath M, et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994;344:1470-2.
25. Herrlich P, Pals S, Ponta H. CD44 in colon cancer. Eur J Cancer 1995;31:1110-12.
26. Weg-Remers S, Anders M, von Lampe B, et al. Decreased expression of CD44 splicing variants in advanced colorectal carcinomas. Eur J Cancer 1998;34:1607-11.
27. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10.
28. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-15.
29. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133+ metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118:2111-20.
30. Baumhoer D, Zlobec I, Tornillo L, et al. Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater. Virchows Arch 2008;453:579-88.
31. Ruemmele P, Dietmaier W, Terracciano L, et al. Histopathologic features and microsatellite instability of cancers of the papilla of Vater and their precursor lesions. Am J Surg Pathol 2009;33:691-704.
32. Zlobec I, Steele R, Terracciano L, et al. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007;60:1112-16.
33. Scarpa A, Di Pace C, Talamini G, et al. Cancer of the ampulla of Vater: chromosome 17p allelic loss is associated with poor prognosis. Gut 2000; 46:842-8.
34. Gires O, Klein CA, Baeuerle PA. On the abundance of EpCAM on cancer stem cells. Nat Rev Cancer 2009;9:143.
35. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007;96:417-23.
36. van der Gun BT, Melchers LJ, Ruiters MH, et al. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 2010;31:1913-21.
37. Spizzo G, Obrist P, Ensinger C, et al. Prognostic significance of Ep-CAM and Her-2/ neu overexpression in invasive breast cancer. Int J Cancer 2002;98:883-8.
38. Brunner A, Prelog M, Verdofer I, et al. EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J Clin Pathol 2008;61:307-10.
39. Prince S, Zeidman A, Dekel Y, et al. Expression of epithelial cell adhesion molecule in gallbladder carcinoma and its correlation with clinicopathological variables. Am J Clin Pathol 2008;129:424-9.
40. Varga M, Obrist P, Schneeberger S, et al. Overexpression of epithelial cell adhesion molecule antigen in gallblader carcinoma is an independent marker for poor survival. Clin Cancer Res 2004;10:3131-6.
41. Stoecklein NH, Siegmund A, Scheunemann P, et al. Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker. BMC Cancer 2006;6:165.
42. Prang N, Preithner S, Brischwein K, et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer 2005;92:342-9.
43. Mosolits S, Markovic K, Frödin JE, et al. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin Cancer Res 2004;10:5391-402.
44. Scheunemann P, Stoecklein NH, Rehders A, et al. Frequency and prognostic significance of occult tumor cells in lymph nodes in patients with adenocarcinoma of the papilla of Vater. HPB (Oxford) 2007;9:135-9.
45. Fong D, Steurer M, Obrist P, et al. Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol 2008;61:31-5.
46. Maetzel D, Denzel S, Mack B, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009;11:162-71.
47. Wielenga VJ, Smits R, Korinek V, et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 1999;154:515-23.
48. Hao J, Chen H, Madigan MC, et al. Co-expression of CD147 (EMMPRIN), CD44v3e10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer 2010;103:1008-18.
49. Hsu KH, Tsai HW, Shan YS, et al. Significance of CD44 expression in gastrointestinal stromal tumors in relation to disease progression and survival. World J Surg 2007;31:1438-44.
50. Lai CH, Shan YS, Sy ED, et al. The significance of CD44 expression in gastrointestinal neuroendocrine tumors. Hepatogastroenterology 2005;52:1071-6.
51. Weichert W, Knösel T, Bellach J, et al. ALCAM / D166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004;57:1160-4.
52. Kojima M, Ishii G, Atsumi N, et al. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 2008;99:1578-83.
53. Horst D, Kriegl L, Engel J, et al. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008;99:1285-9.
54. Salnikov AV, Gladkirch J, Moldenhauer G, et al. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 2010;126:950-8.